DOP70: Crohn’s Disease Like Inflammation of The Pouch is a Distinct Type of PouchitisECCO’23 Copenhagen 2023
DOP71: TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative ColitisECCO’23 Copenhagen 2023
DOP72: HLA-DQA1*05 associates with immunogenicity and loss of response to anti-TNF therapy in the IBD population: A meta-analysisECCO’23 Copenhagen 2023
DOP73: Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)ECCO’23 Copenhagen 2023
DOP74: Artificial Intelligence Quantifying Endoscopic Severity of Ulcerative Colitis in Gradation ScaleECCO’23 Copenhagen 2023
DOP75: Video capsule endoscopy may detect active small bowel Crohn’s disease requiring change of treatment despite unremarkable ileo-colonic anastomosisECCO’23 Copenhagen 2023
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapyECCO’23 Copenhagen 2023
DOP77: Is durable remission achievable after ileocolic resection for Crohn’s disease ? Long-term results of a prospective multicentric cohort study of the GETAID ChirurgieECCO’23 Copenhagen 2023
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scoresECCO’23 Copenhagen 2023
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapyECCO’23 Copenhagen 2023
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).ECCO’23 Copenhagen 2023
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study ResultsECCO’23 Copenhagen 2023
DOP88: Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn’s diseaseECCO’23 Copenhagen 2023
DOP89: Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide studyECCO’23 Copenhagen 2023